Invention Grant
US07884085B2 Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
有权
递送AS-寡核苷酸微球以诱导树突细胞耐受治疗自身免疫性1型糖尿病
- Patent Title: Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
- Patent Title (中): 递送AS-寡核苷酸微球以诱导树突细胞耐受治疗自身免疫性1型糖尿病
-
Application No.: US11127360Application Date: 2005-05-12
-
Publication No.: US07884085B2Publication Date: 2011-02-08
- Inventor: Larry R. Brown , Vered Bisker-Leib , Terrence L. Scott , Debra Lafreniere , Jennifer Machen , Nick Giannoukakls
- Applicant: Larry R. Brown , Vered Bisker-Leib , Terrence L. Scott , Debra Lafreniere , Jennifer Machen , Nick Giannoukakls
- Applicant Address: US IL Deerfield CH Glattpark (Opfikon) US PA Pittsburgh
- Assignee: Baxter International Inc.,Baxter Healthcare S.A.,University of Pittsburgh-of the Commonwealth System of Higher Education
- Current Assignee: Baxter International Inc.,Baxter Healthcare S.A.,University of Pittsburgh-of the Commonwealth System of Higher Education
- Current Assignee Address: US IL Deerfield CH Glattpark (Opfikon) US PA Pittsburgh
- Agency: Marshall, Gerstein & Borun LLP
- Main IPC: A01N43/04
- IPC: A01N43/04 ; C07H21/04 ; A61K9/14
Abstract:
AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to prevent an autoimmune diabetes condition in NOD mice in vivo and in situ. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.
Public/Granted literature
Information query
IPC分类:
